On September 15, 2026 BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, reported updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer (NSCLC) patients with secondary epidermal growth factor receptor (EGFR) resistance mutations such as EGFR C797S. The data were highlighted in a mini-oral presentation at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer in Seoul, South Korea.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR inhibitor designed to overcome the limitations of currently approved EGFR inhibitors for the treatment of EGFR-mutant NSCLC. In patients with EGFR C797S-positive resistance to prior EGFR inhibitor treatment, with or without concurrent T790M, BH-30643 demonstrated a 45% objective response rate (ORR; 18/40) and an 88% disease control rate (DCR; 35/40). At the time of efficacy follow-up, 63% (25/40) of patients remained on treatment with a median follow-up of 6.9 months. BH-30643 also demonstrated a favorable safety profile with low rates of dose reduction or discontinuation due to treatment-related adverse events.

"C797S-driven resistance to third-generation EGFR inhibitors was first described over 10 years ago, yet patients whose tumors develop this mutation currently have no approved targeted treatment options," said Hidehito Horinouchi, M.D., Ph.D., National Cancer Center Hospital, Tokyo, and presenting author of the study. "The responses observed with BH-30643 in this heavily pretreated population, together with encouraging early evidence of durability, support the potential of BH-30643 to directly target this resistance mechanism. These results are particularly encouraging given the need for new precision treatment options that can extend the benefits of targeted therapy for patients with EGFR-mutant lung cancer."

"These updated results provide important clinical validation of the approach we took in intentionally designing BH-30643 to address on-target EGFR resistance, including C797S," said Geoff Oxnard, M.D., Chief Medical Officer of BlossomHill Therapeutics. "We are encouraged to see meaningful anti-tumor activity across a molecularly diverse group of patients with C797S-positive disease, including patients with concurrent T790M and those who have received multiple prior therapies, with a favorable safety profile. Together with the recent FDA Fast Track designation, these data strengthen our conviction in the potential of BH-30643 and support our plans to advance into a Phase 2 trial in patients with C797S-positive NSCLC in 2027."

Presentation highlights:

As of the May 12, 2026 data cutoff, with efficacy follow-up through August 10, 2026:

Encouraging anti-tumor activity was observed in patients with C797S-positive resistance. Among 40 patients with EGFR C797S-positive resistance to prior EGFR inhibitor treatment, with or without concurrent T790M, 18 patients achieved a confirmed (16) or ongoing unconfirmed (2) partial response, representing an ORR of 45% (95% CI: 29%-62%). The DCR was 88% (35/40), and 25 patients (63%) remained on treatment at the time of efficacy follow-up. Median follow-up was 6.9 months.
Activity was observed across a clinically heterogeneous, previously treated population. Patients had received a median of two prior lines of therapy; 98% had received prior osimertinib, 53% had received prior chemotherapy and/or an antibody-drug conjugate, and 53% had a history of brain metastases. 35% of patients had concurrent T790M.
BH-30643 demonstrated a favorable safety profile at expansion doses. Among 174 patients treated at doses of 40 mg, 50 mg and 60 mg twice daily, treatment-related dose reductions and discontinuations occurred in 9% and 3% of patients, respectively. EGFR wild-type-associated treatment-related adverse events were primarily Grade 1. The most common treatment-related adverse event was bilirubin elevation, which was generally asymptomatic and predominantly unconjugated, consistent with UGT1A1 inhibition by BH-30643.
Development of BH-30643 is continuing across multiple EGFR-mutant populations. Expansion cohorts are evaluating on-target resistance mutations, targeted therapy-naive patients and BH-30643 in combination with chemotherapy. BlossomHill plans to initiate a global Phase 2 study targeting EGFR C797S-positive NSCLC in Q1 2027.
The presentation is available on the company’s Posters & Presentations page here: View Source

About BH-30643
BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR inhibitor for the treatment of EGFR-mutant NSCLC. BH-30643 was designed to overcome the limitations of currently approved EGFR inhibitors, which were discovered over a decade ago without the current, modern understanding of the structure and protein dynamics of mutant EGFRs. In preclinical studies, BH-30643 demonstrated potent inhibitory activity across diverse EGFR mutation categories – classical mutations, on-target resistance mutations such as C797S with or without T790M, atypical mutations and exon 20 insertions – while maintaining marked selectivity over wild-type EGFR. BH-30643 has received Fast Track designation and is being evaluated in SOLARA, a global Phase 1/2, first-in-human clinical trial spanning more than 40 sites in 10 countries. Ongoing dose expansion cohorts are enrolling in both TKI-pretreated and TKI-naive settings, including a C797S resistance cohort. For additional information on SOLARA, including a list of study sites and how to enroll, please visit clinicaltrials.gov (NCT06706076).

About the SOLARA Trial
The Phase 1/2 SOLARA clinical trial (NCT06706076) is a global, open label, multicenter study assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). Phase 1 will determine the recommended Phase 2 dose (RP2D) of BH-30643 as a monotherapy and in combination with chemotherapy. Phase 2 is designed to evaluate the antitumor efficacy and safety in specified cohorts determined by mutation subtypes and/or treatment history at the RP2D, as well as the population pharmacokinetics.

(Press release, BlossomHill Therapeutics, SEP 15, 2026, View Source [SID1234670888])

On September 15, 2026 Remedy Plan Therapeutics ("Remedy Plan"), a clinical-stage biotechnology company developing novel therapies that target fundamental metabolic vulnerabilities in disease, reported clinical progress for lead asset RPT1G, a first-in-class hyperbolic NAMPT inhibitor, and provided corporate updates. In the Phase 1 dose escalation trial evaluating RPT1G in relapsed/refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), patients enrolled in Cohort 1 have successfully completed the first full 28-day treatment cycle, and the company has now initiated enrollment in Cohort 2. In addition, the U.S. Food and Drug Administration (FDA) has accepted Remedy Plan’s Investigational New Drug (IND) application for RPT1G for the treatment of solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RPT1G targets NAMPT, an enzyme involved in cellular metabolism and energy production. Prior approaches to NAMPT inhibition have been limited by toxicity. RPT1G is designed to modulate NAMPT activity through a hyperbolic inhibition mechanism, with the goal of enabling therapeutic activity while maintaining tolerability.

"Our progress to date in this trial marks the first time that therapeutic NAMPT inhibition, without limiting toxicity, has been successfully achieved in patients with cancer for longer than just a few days. This represents a significant scientific advancement that had previously been considered impossible to accomplish," said Greg Crimmins, PhD, Founder and CEO of Remedy Plan. "Concurrently, the FDA’s acceptance of our IND application for RPT1G for the treatment of solid tumors marks an important milestone for patients and the growth of Remedy Plan, as we believe our novel approach to NAMPT inhibition unlocks value across the entire spectrum of oncology."

Dr. Crimmins continued, "In addition, we are very excited to have Dr. Oleg Zernovak join Remedy Plan, bringing over 20 years of clinical development experience at leading pharmaceutical and biotechnology companies. Oleg’s expertise in hematologic malignancies, with direct experience managing clinical trials in AML and MDS, will be deeply valuable as we advance RPT1G and expand our emerging pipeline of first-in-class NAMPT inhibitors. Meanwhile, the closing of our Series A extension directly supports our ability to generate deeper and strategically actionable data from the ongoing Phase 1 trial during this upcoming year of growth for our company."

The Phase 1 trial is an ongoing multi-center, open-label, dose escalation study in patients with R/R AML and HR-MDS assessing the safety, tolerability, pharmacokinetics, and pharmacologic activity of RPT1G. The study follows a traditional 3+3 dose escalation design, with the option to add additional patients to dosing cohorts after they clear their respective safety review.

Corporate Updates

Remedy Plan reported the closing of Series A extension financing totaling approximately $30 million, with participation from Schooner Capital and primarily existing investors. Proceeds from the financing will be used to accelerate the advancement of RPT1G, including expanding patient volume in the ongoing Phase 1 study in hematology, initiation of clinical activities around expansion into solid tumors, and support the continued development of proprietary NAMPT inhibitors across additional indications.

In addition, Remedy Plan reported the appointment of Oleg Zernovak, M.D. as Vice President, Clinical Development. Dr. Zernovak brings more than 20 years of drug development experience with expertise in hematologic malignancies and clinical trial execution. Most recently, Dr. Zernovak served as Executive Director, Hematology Clinical Development at BeOne Medicines, where he led clinical and medical oversight in early development in AML and MDS and provided clinical leadership for regulatory engagements. Previously, Dr. Zernovak served as a Vice President, Clinical Development for Curis, where he contributed to clinical strategy for assets in AML, MDS, and solid tumors. Earlier in his career, Dr. Zernovak served as a Senior Medical Director, Early Development, Hematologic Malignancies at Cellectis and Janssen. Dr. Zernovak also served as Medical Director at Daiichi-Sankyo, Celgene Corporation, and Novartis Oncology. Dr. Zernovak received his M.D. degree from Azerbaijan State Medical Academy.

About RPT1G
RPT1G is a novel small-molecule NAMPT inhibitor designed to selectively target cancer cell metabolism while avoiding the on-target toxicities that have historically limited NAMPT inhibitors. The drug utilizes a unique hyperbolic inhibition mechanism that allows controlled modulation of NAMPT activity rather than complete enzyme shutdown. This approach is designed to maintain metabolic function in healthy cells while disrupting the metabolic vulnerabilities of cancer cells.

(Press release, Remedy Plan, SEP 15, 2026, View Source [SID1234670886])

On September 15, 2026 Kestrel Therapeutics Inc. ("Kestrel" or the "Company"), a clinical-stage biotechnology company developing next-generation small-molecule inhibitors targeting mutant KRAS, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to KST-6051, a potential best-in-class, oral pan-KRAS inhibitor, for the treatment of patients with advanced or metastatic solid tumors harboring KRAS mutations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fast Track is a designation created to facilitate the development and expedite the review of drugs intended to treat serious conditions and address an unmet medical need. Companies that receive Fast Track designation benefit from more frequent communication with the FDA throughout development, and may be eligible for Accelerated Approval, Priority Review, and rolling review of a New Drug Application (NDA), provided relevant criteria are met.

"FDA Fast Track designation for KST-6051 is an important regulatory milestone for Kestrel, based on the strength of our preclinical data package. This designation will allow us to work more closely with the FDA as we advance KST-6051 through our ongoing Phase 1 study, with the goal of bringing a much-needed treatment option to patients with KRAS-mutant tumors as efficiently as possible," said Frank Haluska, MD, PhD, President and Chief Executive Officer of Kestrel Therapeutics.

KST-6051 is being evaluated in an ongoing first-in-human (FIH), dose-escalation Phase 1 study, denoted FALCON (NCT07458347) in patients with advanced or metastatic KRAS-mutant solid tumors.

About Fast Track Designation

The FDA’s Fast Track program is designed to facilitate development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to patients earlier. Fast Track addresses a broad range of serious conditions, and a drug that receives Fast Track designation is eligible for more frequent meetings and written communication with the FDA, as well as the possibility of Priority Review and rolling submission of a marketing application.

About KST-6051

KST-6051 is a potential best-in-class, oral pan-KRAS inhibitor, developed for the treatment of KRAS-driven cancers. KST-6051 is a potent and selective inhibitor of KRAS with activity against KRAS in both its active (GTP-bound) and inactive (GDP-bound) states. Preclinical data demonstrate robust on-target pathway modulation, anti-proliferative activity, and efficacy at well-tolerated doses in multiple human KRAS mutant tumor models. The Company is initiating a Phase 1 study in patients with KRAS-mutant advanced/metastatic solid tumors. Its clinical development will ultimately address pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and other KRAS-driven malignancies.

(Press release, Kestrel Therapeutics, SEP 15, 2026, View Source [SID1234670885])

On September 15, 2026 Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, reported positive preliminary preclinical results for ERNA-201, its synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapy engineered to express anti-inflammatory factors, while outlining a sharpened oncology strategy designed to accelerate the Company’s transition into the clinic and expand the long-term potential of its proprietary synthetic iMSC platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In preliminary studies using the collagen-induced arthritis (CIA) model, an industry-standard preclinical model for rheumatoid arthritis and inflammatory joint disease, several ERNA-201 lead candidates demonstrated reductions in disease severity relative to untreated controls, including improvements in clinical arthritis scores consistent with the therapy’s intended anti-inflammatory mechanism of action.

Ernexa believes these results represent an important scientific milestone: ERNA-201 demonstrated meaningful preclinical proof-of-concept in inflammatory disease, providing additional evidence that the Company’s engineered iMSC platform can be programmed to deliver therapeutically relevant factors across distinct disease settings.

With this platform validation in hand, Ernexa is concentrating its near-term capital and operational resources on what management believes represents the Company’s most immediate opportunity to create value for patients and shareholders: advancing ERNA-101 into a first-in-human clinical study in platinum-resistant ovarian cancer (PROC).

Importantly, the decision to prioritize ERNA-101 does not reflect a change in Ernexa’s conviction in ERNA-201 or its underlying biology. Rather, following the positive ERNA-201 proof-of-concept results, the Company believes it has reached an appropriate point to preserve the program while directing near-term resources toward achieving clinical validation of its platform in oncology.

"We believe the ERNA-201 results are an important validation of both the program and the broader potential of our synthetic iMSC platform," said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. "ERNA-201 did what we wanted to see at this stage: it generated an encouraging proof-of-concept signal in an established inflammatory disease model and demonstrated the potential to engineer our iMSCs for therapeutic activity beyond cancer. That success gives us the confidence to preserve the significant future opportunity represented by ERNA-201 while concentrating our resources on the milestone directly ahead of us, bringing ERNA-101 into the clinic."

Mr. Luther continued, "Our objective is bigger than advancing a single candidate. We are building a differentiated oncology company around a scalable, off-the-shelf cell therapy platform. With ERNA-101 on track for FDA IND submission before year end, we believe Ernexa is approaching a potentially defining inflection point. We intend to execute against that milestone with urgency while broadening our oncology pipeline and identifying additional cancers where our platform could make a meaningful difference."

ERNA-201: Positive Data Strengthen Validation of Ernexa’s iMSC Platform

ERNA-201 is engineered to express anti-inflammatory factors designed to target inflammation and treat autoimmune disease. In completed preliminary studies, ERNA-201 was evaluated in the CIA model, which is widely used to assess potential therapies for rheumatoid arthritis and other inflammatory joint diseases.

Mice treated with several ERNA-201 lead candidates demonstrated reductions in disease severity relative to untreated controls, including improvements in clinical arthritis scores. Ernexa believes the findings are consistent with the candidate’s intended anti-inflammatory mechanism and provide meaningful proof-of-concept support for the use of synthetic, cytokine-engineered iMSCs in inflammatory and autoimmune disease.

"Seeing disease-modifying activity from ERNA-201 in the collagen-induced arthritis model is an encouraging scientific result," said Robert H. Pierce, M.D., Chief Scientific Officer of Ernexa Therapeutics. "These findings support the underlying thesis that engineered iMSCs can serve as a versatile therapeutic delivery platform. We designed ERNA-201 to deliver anti-inflammatory factors in disease, and the preliminary activity we observed is consistent with that objective. From a scientific perspective, these data increase our confidence in the program and provide another important validation point for the broader platform."

The ERNA-201 results are particularly important to Ernexa because the program employs the same fundamental synthetic iMSC platform architecture that underpins the Company’s broader pipeline. While ERNA-201 is engineered for anti-inflammatory activity and ERNA-101 is engineered to stimulate an immune response against cancer, both programs demonstrate the potential versatility of an allogeneic, scalable cell platform that can be engineered for distinct therapeutic purposes.

Building Momentum Toward the Clinic: ERNA-101 Advancing Toward Planned IND Submission in Q4 2026

With ERNA-201 generating positive preliminary proof-of-concept data, Ernexa is prioritizing the next major milestone in the Company’s evolution: advancing ERNA-101 toward a planned IND submission for a first-in-human clinical study in platinum-resistant ovarian cancer.

ERNA-101 is Ernexa’s lead oncology cell therapy candidate, engineered to express an IL-7/IL-15 fusion cytokine designed to activate and regulate the immune system’s response to recognize and attack cancer cells.

The Company is focused on advancing ERNA-101 toward a planned IND submission in the fourth quarter of 2026. Ernexa believes achieving this milestone would represent an important step toward the Company’s transition from a preclinical development company to a clinical-stage oncology company and the generation of human clinical evidence necessary to evaluate the therapeutic potential of its platform.

Clinical data from the ERNA-101 PROC study are expected in Q4 2027, providing the Company with a series of potential clinical and operational milestones over the coming 12–18 months.

A Focused Oncology Strategy Built Around One Scalable Platform

Ernexa’s strategy extends beyond a single indication or product candidate. The Company’s proprietary platform begins with induced pluripotent stem cells (iPSCs), which are engineered and transformed into synthetic induced mesenchymal stem cells. The resulting allogeneic iMSCs are designed to provide a scalable, off-the-shelf therapeutic approach without the need for patient-specific cell harvesting.

Management believes this architecture creates the potential to engineer iMSCs with different therapeutic factors and apply the platform across multiple diseases. The positive preliminary ERNA-201 findings provide additional support for that platform thesis, while ERNA-101 now represents the Company’s most advanced opportunity to demonstrate its potential in patients.

As Ernexa moves toward the clinic, the Company intends to broaden the scope of its oncology program by evaluating additional high-need cancer indications and advancing next-generation iMSC candidates designed to build on the Company’s existing scientific and manufacturing capabilities.

The Company will prioritize opportunities based on scientific rationale, unmet patient need, commercial potential and capital efficiency, including opportunities that may be pursued internally or through strategic collaborations.

Disciplined Capital Allocation: Advancing the Nearest Value-Creating Milestones

Following the encouraging ERNA-201 results, Ernexa has elected to pause additional preclinical development expenditures on ERNA-201 at this time and preserve the program while concentrating near-term resources on ERNA-101 and the expansion of its oncology pipeline.

The decision is a capital allocation priority rather than a scientific decision to discontinue ERNA-201. The Company believes the positive preliminary results provide a foundation from which ERNA-201 could potentially be advanced in the future as resources, strategic priorities and development opportunities warrant.

"We have achieved an important objective with ERNA-201 by generating encouraging proof-of-concept data," Luther said. "The question for us now is not whether we believe in the program. We do. The question is where each incremental dollar and each hour of our team’s effort can have the greatest impact today. With ERNA-101 approaching the clinic, we believe concentrating resources behind first-patient dosing and expanding our oncology opportunity is the most disciplined path forward."

"We are preserving ERNA-201’s future potential while accelerating the program that is closest to human clinical validation. We believe that the combination of scientific validation, disciplined execution and a clear path into the clinic positions Ernexa for an important next chapter."

Multiple Potential Catalysts Ahead

Over the coming 12–18 months, Ernexa intends to:

Submit ERNA-101 IND in Q4 2026 for a first-in-human clinical study in platinum-resistant ovarian cancer;
Generate clinical data from the ERNA-101 PROC program, currently expected in Q4 2027;
Continue generating translational and preclinical evidence designed to strengthen validation of the synthetic iMSC platform;
Evaluate opportunities to expand the platform into additional high-need oncology indications;
Advance next-generation synthetic iMSC oncology candidates;
Explore strategic collaborations that could accelerate or broaden the application of Ernexa’s technology; and
Maintain disciplined capital allocation focused on milestones management believes can create the greatest value for patients and shareholders.
"We believe we are entering one of the most consequential periods in Ernexa’s development," Luther concluded. "ERNA-201 has provided encouraging evidence that our engineering approach can translate into therapeutic activity in a well-established disease model. ERNA-101 is approaching the clinic. And behind it is a platform we believe can be engineered and deployed against multiple high-need cancers. Our focus now is execution, reaching the clinic, generating human data and building a broader oncology pipeline capable of creating sustainable value."

(Press release, Ernexa Therapeutics, SEP 15, 2026, View Source [SID1234670884])

On September 15, 2026 KORTUC INC., a clinical-stage oncology biotechnology company developing an investigational intratumoral radiosensitizer, reported that it has achieved its target enrollment of 184 patients in its registrational, randomized Phase II breast cancer trial. The study is now moving toward patient follow-up, data analysis, and an efficacy readout targeted for 2027. The news comes following a Series B round and broader company update: KORTUC now has three clinical studies advancing in breast, cervical and rectal cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Together, they reflect a growing international development program – including a U.S. academic collaboration with the University of California San Diego, a United Kingdom-led breast cancer trial and a newly authorized France-based rectal cancer study, with additional trial sites in India and Thailand.

KRC-01, a proprietary intratumoral formulation based on hydrogen peroxide and sodium hyaluronate, addresses hypoxia – or lack of oxygen – a problem for over 50% of solid tumors. It is designed to raise oxygen levels within tumors and inactivate antioxidative enzymes that contribute to radioresistance. Sodium hyaluronate slows the decomposition of hydrogen peroxide, helping the formulation remain within the tumor as radiation treatment is delivered.

Three clinical programs advancing globally

Breast cancer trial reaches 184-patient enrollment target: The breast cancer trial is led by The Institute of Cancer Research in the United Kingdom. The study’s primary endpoint is complete response – no detectable tumor on MRI after treatment, a particularly meaningful outcome for patients with locally advanced or recurrent disease. It compares radiotherapy alone with radiotherapy plus KRC-01 in patients with primary or recurrent locally advanced breast cancer. The study is being conducted through six centers in the United Kingdom and four centers in India (NCT03946202).

"Reaching our 184-patient enrollment target is a defining milestone for KORTUC," said Kazu Matsuda, CEO of KORTUC. "It moves our lead program beyond target recruitment and toward data readout, while our cervical and rectal studies expand the evaluation of KRC-01 into two additional cancers. Through clinical collaborations in the United States, United Kingdom and France, we are building the global evidence needed to assess KRC-01 across tumors where hypoxia can limit radiation response."

Cervical cancer – global study with U.S. academic collaboration: KORTUC’s ongoing global Phase 1/2 study, conducted in partnership with the University of California San Diego, is evaluating KRC-01 with standard chemoradiotherapy in 70 patients with untreated, locally advanced cervical cancer. Following first enrollment in March 2026, the study is progressing through a 10-patient safety and dose-schedule phase before a 60-patient randomized phase comparing standard treatment with or without KRC-01. The randomized phase will primarily evaluate progression-free survival (PFS), while also assessing overall survival (OS) and quality of life, examining whether adding KRC-01 can translate into meaningful longer-term benefits for patients. Registry sites are listed in Thailand, India and the United Kingdom (NCT05570422).

Rectal cancer – France: The Phase II K-BOOST clinical trial has received authorization to proceed in France and is expected to begin enrollment following site activation. Sponsored by Gustave Roussy, the study will enroll 24 adults with non-metastatic, high-risk stage III rectal cancer at Gustave Roussy and Institut Bergonié. Participants will receive eight intratumoral KRC-01 injections alongside standard long-course chemoradiotherapy, followed by consolidation chemotherapy. The primary endpoint is the clinical complete response rate at week 24. The study will explore whether adding KRC-01 can support an organ-preservation pathway for patients while retaining surgery as an established treatment option. K-BOOST is registered under EU Clinical Trial number 2025-524378-40-00 and ClinicalTrials.gov identifier NCT07622017.

KRC-01 is an investigational product and has not been approved for commercial use. For more information about KORTUC and its clinical development program, visit KORTUC.com.

(Press release, KORTUC, SEP 15, 2026, View Source [SID1234670883])